日本干眼症市场规模、份额、趋势及预测（依疾病类型、药物类型、产品类型、通路及地区划分），2026-2034年

预计到 2025 年，日本干眼症市场价值将达到 1.501 亿美元，到 2034 年将达到 2.021 亿美元，2026 年至 2034 年的复合年增长率为 3.4%。

由于眼表疾病病例持续增加，日本干眼症问题日益严重，因此日本干眼症市场正经历显着成长。日本人口老化速度加快，各年龄层使用电子设备的比例也越来越高。这导致人们对有效解决方案的需求日益增长，从而推动了日本干眼症市场的发展。眼科研究的进步以及治疗方法的改进也促进了日本干眼症市场份额的成长。

主要结论与见解：

• 依疾病类型划分：蒸发性干眼症在 2025 年占据市场主导地位，市占率达 60%。这主要是由于日本老龄人口中睑板腺功能障碍的高发生率以及长时间接触电子萤幕，导致泪膜不稳定。
• 按药物类型划分：润滑眼药水将在 2025 年占据 49% 的市场份额，这得益于其广泛的非处方购买管道、使用方便以及作为治疗轻度至中度干眼症状的一线疗法的既定地位。
• 按产品类型划分，到 2025 年，液体眼药水将占 55% 的市场份额，这反映出消费者强烈偏好能够快速起效、即时缓解症状并适应不同生活方式和治疗习惯的配方。
• 按分销管道划分：到 2025 年，零售药局将占据市场主导地位，市场份额将达到 46%，这得益于其在日本各地社区药局网路中提供的便利性和可靠的非处方眼科护理产品。
• 主要参与者：日本干眼症市场竞争强度适中，成熟的製药公司和专业的眼科公司竞相透过产品创新、配方技术进步和策略联盟来扩大市场份额。

随着医疗服务提供者、研究人员和患者对干眼症复杂性的认识不断加深，并开始关注其治疗的各个方面，日本的干眼症市场也持续发展。 2023年6月，千住製药株式会社与生物製药公司Novalic签署许可协议，共同开发、生产和销售NOV03（全氟己辛烷眼用溶液），这是一款突破性的无防腐剂干眼症治疗药物，专为日本市场打造。该药物是第一个能够直接抑制干眼症泪液蒸发的治疗方法。日本拥有完善的医疗基础设施，并采用先进的诊断设备来检测干眼症。对无防腐剂配方、创新黏蛋白分泌促进剂和泪液稳定剂的重视，显示有效的眼科护理方法正在被广泛采用。数位科技也正在融入传统的眼科护理中，使患者能够更方便地获得个人化的治疗方案。有关眼部健康重要性的教育活动也促进了各种干眼症治疗方法的普及。

日本干眼症市场趋势：

对不含防腐剂的眼科製剂的需求日益增长

在日本，随着人们对防腐剂对眼表不良影响（包括角膜上皮损伤和长期使用加重症状）的认识不断提高，不含防腐剂的眼药水的使用量显着增加。患者和医护人员都越来越倾向于选择较温和的配方来治疗慢性干眼症。药局和医院广泛供应一次性无防腐剂人工泪液和治疗性眼药水，反映了临床指南的演变和患者偏好的转变，进一步增强了日本对安全且耐受性良好的眼科製剂的需求。

扩大泪膜导向治疗方法的应用

日本在采用泪膜导向的诊断和治疗策略方面处于领先地位，该策略着眼于解决干眼症的根本原因，而不仅仅是缓解症状。这种方法评估泪膜的破坏模式，并制定个人化的治疗方案，以恢復泪液稳定性、房水量和黏蛋白分泌。基于此，泪膜导向诊断（TFOD）和泪膜导向治疗（TFOT）的概念最初在日本开发并广泛应用，能够根据泪膜动力学和破坏模式对干眼症亚型进行分类，从而指导更精准、更具针对性的干预措施。眼科、验光和生活方式咨询相结合的多学科诊疗模式的日益融合，正在推动日本干眼症市场的成长，并支持针对不同亚型疾病的标靶干预措施的发展。

数位产品引起的眼部疲劳导致的干眼症正日益受到关注。

在日本，电子设备在职场和日常生活中的广泛使用导致萤幕相关干眼症状急剧增加，尤其是在年轻人和工作年龄层中。长时间使用萤幕会降低眨眼频率，导致泪液不稳定，并加速干眼症的发生。例如，日本大规模人口研究报告称，每天使用影片显示终端（VDT）超过5小时的人群，其干眼症盛行率显着高于每天萤幕使用时间较短的人群，女性患病率约为36.5%，男性约为22.3%。这表明长时间使用电子萤幕与干眼症状之间存在关联。医疗保健专业人员正越来越多地将数位眼部疲劳评估纳入常规眼科检查，同时进行的宣传宣传活动也在推广预防措施，例如定期休息、调整环境以及使用合适的润滑剂。

2026-2034年市场展望：

受人口老化、萤幕使用导致的眼睛不适加剧以及泪液管理临床方法不断发展的推动，日本干眼症市场预计将持续成长。各年龄层眼部健康意识提升，以及先进诊断工具和治疗方案的普及，正在改善治疗环境。政府主导的、旨在促进眼部预防保健的医疗政策，以及患者在慢性病管理中日益增强的参与度，进一步巩固了该市场的长期成长势头。预计到2025年，该市场规模将达到1.501亿美元，到2034年将达到2.021亿美元，2026年至2034年的复合年增长率（CAGR）为3.4%。

1. 日本干眼症市场规模有多大？

2. 日本干眼症市场的预期成长率是多少？

3. 在日本干眼症市场中，哪一种疾病类型所占的份额最大？

4.推动市场成长的关键因素是什么？

5. 日本干眼症市场面临的主要挑战是什么？

目录

第一章：序言

第二章：调查范围与调查方法

• 调查目标
• 相关利益者
• 数据来源
• 市场估值
• 调查方法

第三章执行摘要

第四章 引言

• 概述
• 主要行业趋势

第五章：日本干眼症市场

• 市场概览
• 市场表现
• 新冠疫情的影响
• 市场预测

第六章 依疾病类型分類的市场区隔

• 蒸发性干眼症
• 干眼症

第七章 依药物类型分類的市场区隔

• 抗发炎药
• 润滑眼药水
• 自体血清眼药水

第八章 产品市场细分

• 眼药水
• 凝胶
• 液体擦拭巾
• 眼膏
• 其他的

第九章 按分销管道分類的市场细分

• 医院药房
• 零售药房
• 网路药房

第十章 按地区分類的市场细分

• 关东地区
• 近畿地区
• 中部地区
• 九州和冲绳地区
• 东北部地区
• 中国地区
• 北海道地区
• 四国地区

第十一章 SWOT 分析

• 概述
• 优势
• 弱点
• 机会
• 威胁

第十二章 价值链分析

第十三章 波特五力分析

• 概述
• 买方的议价能力
• 供应商的议价能力
• 竞争程度
• 新进入者的威胁
• 替代品的威胁

第十四章：定价分析

第十五章 政策与监管环境

第十六章 竞争格局

• 市场结构
• 主要企业
• 主要企业简介

The Japan dry eye syndrome market size was valued at USD 150.1 Million in 2025 and is projected to reach USD 202.1 Million by 2034, growing at a compound annual growth rate of 3.4% from 2026-2034.

The Japan dry eye syndrome market is witnessing significant growth with the increasing problem of dry eyes in the country due to the ever-increasing cases of ocular surface disorders. The Japanese population is aging at a rapid pace, and the use of digital gadgets is common among all ages. This is fueling the growth of the Japan dry eye syndrome market, with an increase in the need to find the best solutions to this problem. The developments in the study of the eyes and the changing face of the way the problem is being dealt with are all adding to the growth of the Japan dry eye syndrome market share.

KEY TAKEAWAYS AND INSIGHTS:

• By Disease Type: Evaporative dry eye syndrome dominated the market with a share of 60% in 2025 , driven by the high prevalence of meibomian gland dysfunction among Japan's aging population and prolonged digital screen exposure contributing to tear film instability.
• By Drug Type: Lubricant eye drops lead the market with a share of 49% in 2025 , owing to their widespread availability as over-the-counter solutions, ease of use, and established role as the first-line treatment for managing mild to moderate dry eye symptoms.
• By Product: Liquid drops hold the leading market share of 55% in 2025 , reflecting strong consumer preference for convenient, fast-acting formulations that provide immediate symptomatic relief and are compatible with varied lifestyles and treatment routines.
• By Distribution Channel: Retail pharmacies dominate the market with a share of 46% in 2025 , supported by the extensive network of community pharmacies across Japan offering accessible and trusted over-the-counter eye care products.
• Key Players: The Japan dry eye syndrome market features moderate competitive intensity, with established pharmaceutical companies and specialized ophthalmic firms competing through product innovation, formulation advancements, and strategic partnerships to expand their market presence.

The dry eye syndrome market in Japan is moving forward as healthcare providers, researchers, and patients understand the complex nature of the disease and strive to address the various aspects of the condition's management. In June 2023, Senju Pharmaceutical Co., Ltd. entered into a licensing agreement with biopharmaceutical firm Novaliq GmbH to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), a first-in-class, preservative-free treatment that directly targets tear evaporation for dry eye disease in Japan. The country is known to have a well-developed health infrastructure and uses advanced diagnostic tools to detect the disease. Its focus on preservative-free agents, innovative mucin secretagogues, and tear film stabilizers suggests that the country is familiar with methods for effective eye care. Digital technologies are also being integrated into traditional ophthalmological practice, thereby increasing access to individual patient management plans. Awareness campaigns about the importance of eye health have led more people to embrace the various dry eye treatments.

JAPAN DRY EYE SYNDROME MARKET TRENDS:

Rising Demand for Preservative-Free Ophthalmic Formulations

Japan is experiencing a notable shift toward preservative-free eye drops, driven by growing awareness of the adverse effects of preservatives on the ocular surface, including corneal epithelial damage and symptom aggravation during prolonged use. Both patients and clinicians are increasingly favoring gentler formulations for chronic dry eye management. The expanding availability of single-dose preservative-free artificial tears and therapeutic drops across pharmacies and hospitals reflects evolving clinical guidelines and patient preferences, reinforcing the demand for safer, well-tolerated ophthalmic solutions in the country.

Growing Adoption of Tear Film-Oriented Therapeutic Approaches

Japan is at the forefront of adopting tear film-oriented diagnosis and treatment strategies that address the root causes of dry eye rather than merely alleviating symptoms. This approach involves assessing tear film breakup patterns and tailoring therapies to restore tear stability, aqueous volume, and mucin secretion. Building on this paradigm, the concept of tear-film-oriented diagnosis (TFOD) and tear-film-oriented therapy (TFOT), first developed and widely applied in Japan, enables clinicians to classify dry eye subtypes based on tear film dynamics and breakup patterns, guiding more precise, component-targeted interventions. The integration of multi-disciplinary care combining ophthalmology, optometry, and lifestyle guidance is gaining traction, driving Japan dry eye syndrome market growth and encouraging the development of targeted interventions for different subtypes of the condition.

Increasing Focus on Digital Eye Strain-Related Dry Eye

The widespread use of digital devices across workplaces and daily life in Japan is contributing to a surge in screen-related dry eye symptoms, particularly among younger and working-age populations. Extended screen exposure reduces blink frequency and contributes to tear film instability, accelerating dry eye onset. For example, a large population-based study in Japan reported that individuals who used visual display terminals (VDTs) for >=5 hours per day had a significantly higher prevalence of dry eye, with up to around 36.5 % of women and 22.3 % of men affected, compared with those with minimal daily screen time, demonstrating the link between prolonged digital screen use and dry eye symptoms. Healthcare providers are increasingly incorporating digital eye strain assessments into routine eye care, while awareness campaigns are promoting preventive measures such as regular breaks, environmental adjustments, and appropriate lubricant use.

MARKET OUTLOOK 2026-2034:

Japan's dry eye syndrome market is poised for sustained growth, underpinned by the country's aging demographic profile, rising prevalence of screen-related ocular discomfort, and evolving clinical approaches to tear film management. Increasing awareness of eye health across all age groups, combined with expanding access to advanced diagnostic tools and therapeutic options, is strengthening the treatment landscape. Government-led healthcare initiatives promoting preventive eye care, alongside growing patient engagement with chronic disease management, are further reinforcing the long-term growth trajectory of the market. The market generated a revenue of USD 150.1 Million in 2025 and is projected to reach a revenue of USD 202.1 Million by 2034, growing at a compound annual growth rate of 3.4% from 2026-2034.

JAPAN DRY EYE SYNDROME MARKET REPORT SEGMENTATION:

Disease Type Insights:

• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome
• The evaporative dry eye syndrome dominates with a market share of 60% of the total Japan dry eye syndrome market in 2025.
• Evaporative dry eye syndrome, mainly associated with meibomian gland dysfunction, is the most common form of this condition in Japan. The leading share indicates the huge impact of environmental factors, screen time elongation, and age-related glandular changes on tear film stability. The aging demographic profile, together with the rapid spread of digital devices at workplaces and educational institutions, hastens the incidence of evaporative dry eye in Japan. The increasing acknowledgement of lipid layer inadequacy as a major cause in disrupting tear film is fueling demand for specific therapeutic interventions.
• Japanese healthcare providers are increasingly focused on targeted treatments that address the root causes of evaporative dry eye, such as warm compress therapies, lipid-based lubricants, and innovative ophthalmic solutions designed to restore tear film integrity. Clinical focus on the identification and management of meibomian gland dysfunction as a root cause is strengthening diagnostic accuracy and treatment effectiveness. Further reinforcement in the dominance of this segment across both hospital and community-based ophthalmology settings is the growing adoption of advanced imaging technologies for gland assessment.

Drug Type Insights:

• Anti-inflammatory Drugs
• Lubricant Eye Drops
• Autologous Serum Eye Drops
• The lubricant eye drops leads with a share of 49% of the total Japan dry eye syndrome market in 2025.
• Lubricating eye drops remain to be the core therapy for the treatment of dry eye conditions within Japan by providing symptomatic relief for patients belonging to all severity categories. The accessibility and easy availability of the eye drops within retail outlets and hospitals, along with their safety profile, appear to be making the therapy the preferred choice for mild and moderate cases of dry eye. Real-world usage data from a large crowdsourced study in Japan showed that among individuals with symptomatic dry eye, artificial tears were the most commonly used type of eye drop (used by 53.4 % of respondents), followed by hyaluronic acid solutions (33.1 %), highlighting the central role of lubricating drops in everyday management.
• The segment remains to benefit from an ongoing improvement in formulation technology to develop hyaluronic acid ingredients and lipid-enriched lubricants. Preservative-free single-dose forms are showing strong market appeal among patients with frequent-use requirements. They are intended to address the issue of long-term ocular surface safety. The over-the-counter format advantage, along with the growing awareness of the need to keep the eyes hydrated, is augmenting the strong market position of eye lubricating drops.

Product Insights:

• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment
• Others
• The liquid drops dominates with a market share of 55% of the total Japan dry eye syndrome market in 2025.
• The most widely used dry eye treatment product types in Japan continue to be liquid drops due to the associated ease of administration and quick onset of relief. The dry eye treatment segment includes both prescription and non-prescription products, which range from simple artificial tears to complex therapeutic formulas targeting particular deficiencies in the tear film. The Japanese market favors liquid drop-type dry eye treatment products due to customer familiarity and practicality, as it suits all types of dry eye patients, from mild to severe, with either an active or less active lifestyle.
• The continued development of preservative-free single-dose liquid drop formats is further enhancing their position in the market, addressing consumer concerns related to long-term ocular surface safety. Innovative formulations featuring hyaluronic acids, lipid ingredients, and mucin-stimulating agents are increasing the scope of liquid drop therapy beyond primary hydration. The ease of portable formats, their increasing availability in stores, online pharmacies, as well as consumer awareness of correct usage, is keeping demand for liquid drop formats strong.

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• The retail pharmacies leads with a share of 46% of the total Japan dry eye syndrome market in 2025.
• The primary mode of product distribution for dry eye treatment is through retail pharmacies, which take advantage of the already extensive and well-established infrastructure in Japan. This channel is especially advantageous since it allows patients to access the wide product range available in over-the-counter lubricating eye drops and artificial tears from the numerous retail pharmacies available, which cover the entire country and give patients quick access to such dry eye treatment.
• The level of trust placed in pharmacists to give personalized recommendations on product selection and how to use it correctly contributes to a positive perception for the distribution method. The addition of health consultation services within retail pharmacies contributes to higher consumer engagement in the treatment guidelines set for the self-management of chronic eye conditions. The focus on eye health awareness promotions within retail pharmacies, strategic placement of products within the retail environment, as well as the increasing cooperation between pharmaceutical companies and retail pharmacies, all contribute to the continued market dominance of retail pharmacies.

Regional Insights:

• Kanto Region
• Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region
• The Kanto Region leads Japan's dry eye syndrome market, driven by its large urban population concentrated in Tokyo and surrounding metropolitan areas. Extensive healthcare infrastructure, high concentration of ophthalmology specialists, and significant prevalence of screen-related ocular strain among office workers are sustaining strong demand for both prescription and over-the-counter dry eye treatments across the region.
• The Kinki Region represents a significant market share, supported by well-established ophthalmology networks and major medical research institutions in Osaka and Kyoto. Growing awareness of dry eye management, expanding availability of advanced therapeutic options, and rising patient engagement with preventive eye care services are strengthening treatment adoption across urban and suburban communities in the region.
• The Central/Chubu Region is experiencing steady growth in dry eye treatment adoption, fueled by expanding healthcare access and rising digital device usage among the working population. Increasing emphasis on preventive eye care services, growing distribution of ophthalmic products through retail pharmacies, and enhanced diagnostic capabilities at regional hospitals are supporting sustained market development.
• The Kyushu-Okinawa Region is contributing to market expansion through improved regional healthcare delivery and growing public awareness of ocular health. Increasing availability of specialized ophthalmic products in retail and hospital pharmacy settings, along with expanding access to ophthalmology consultations in semi-urban areas, is driving broader adoption of dry eye treatments across the region.
• The Tohoku Region is witnessing gradual growth in the dry eye syndrome treatment market, supported by government initiatives to enhance healthcare accessibility in rural and semi-rural areas. Increasing adoption of modern diagnostic tools at regional eye care facilities and expanding community pharmacy networks are improving patient access to effective dry eye management solutions.
• The Chugoku Region is expanding its dry eye care capabilities through improved distribution of ophthalmic products and growing integration of telemedicine in eye health services. Rising patient engagement with preventive ocular health practices and enhanced awareness campaigns in community settings are encouraging broader treatment adoption across the region's urban and rural populations.
• The Hokkaido Region is advancing dry eye treatment awareness through seasonal health campaigns addressing cold and dry climate-related ocular discomfort. Strengthening pharmacy networks, increasing specialist consultations, and growing adoption of lubricant-based therapies during harsh winter months are supporting steady market growth and improving patient outcomes across the territory.
• The Shikoku Region is demonstrating growth potential through enhanced regional healthcare programs and increasing availability of dry eye treatments in community pharmacies. Rising awareness of chronic eye health management, expanding telemedicine services for remote consultations, and growing emphasis on age-related ocular care are collectively supporting gradual market development across the region.

MARKET DYNAMICS:

Growth Drivers:

• Why is the Japan Dry Eye Syndrome Market Growing ?
• Rapidly Aging Population Driving Higher Disease Prevalence
• Japan's demographic landscape, characterized by one of the world's highest proportions of elderly citizens, is a fundamental growth driver for the dry eye syndrome market. Age-related changes in tear gland function, hormonal shifts, and increased prevalence of systemic conditions such as diabetes and autoimmune disorders directly contribute to higher rates of dry eye among older adults. In fact, clinical research in Japan has shown that among individuals aged over 60, definite dry eye was observed in approximately 73.5 % of eyes examined, highlighting the significantly elevated burden of dry eye in an elderly Japanese population. As the elderly population continues to expand, healthcare systems are adapting by integrating routine eye health screenings into geriatric care programs. Ophthalmologists and primary care providers are increasingly emphasizing early detection and proactive management of dry eye as part of comprehensive elder care. This demographic-driven demand is expected to remain a consistent growth catalyst throughout the forecast period.
• Escalating Digital Device Usage Across All Demographics
• The pervasive use of smartphones, computers, tablets, and other digital devices in Japan's highly connected society is significantly contributing to the rising incidence of dry eye symptoms. Prolonged screen exposure reduces blink frequency, disrupts tear film stability, and accelerates evaporative tear loss, leading to increased discomfort and demand for effective treatments. A cross-sectional study of Japanese office workers found that those using visual display terminals (VDTs) for more than 8 hours per day had a significantly higher risk of dry eye disease and exhibited short tear break-up time (<= 5 seconds), a clinical indicator of tear instability, with 78.6 % of participants showing this sign, highlighting the strong association between extended screen use and ocular surface dysfunction in digital work environments. This trend affects not only working-age adults in office environments but also younger populations engaged in extensive digital learning and entertainment activities.
• Advancements in Ophthalmic Treatment Approaches and Formulations
• Continuous innovation in ophthalmic drug development and treatment methodologies is strengthening the therapeutic landscape for dry eye syndrome in Japan. The evolution from basic artificial tear formulations to advanced mucin secretagogues, diquafosol-based therapies, and lipid-stabilizing solutions represents a significant advancement in addressing the multifactorial nature of the condition. Topical rebamipide ophthalmic suspension (Mucosta(R)) is a clinically validated mucin secretagogue that significantly improves tear stability, corneal staining, tear break-up time, and symptoms, highlighting Japan's role in mechanism-targeted therapies. These newer therapeutic approaches target specific pathophysiological mechanisms, offering more effective and tailored relief compared to conventional treatments. The development of novel drug delivery systems, including preservative-free single-dose formats and sustained-release formulations, is improving patient compliance and treatment outcomes.

Market Restraints:

• What Challenges the Japan Dry Eye Syndrome Market is Facing?
• Underdiagnosis and Low Treatment-Seeking Behavior
• Despite the high prevalence of dry eye in Japan, a significant proportion of affected individuals remain undiagnosed or do not actively seek medical treatment. Many patients perceive dry eye symptoms as minor discomforts rather than a medical condition requiring professional intervention. This underdiagnosis limits market penetration and prevents patients from accessing appropriate therapeutic solutions. Cultural tendencies toward self-management and reluctance to visit specialists for perceived minor ailments further contribute to delayed diagnosis and treatment initiation.
• Reimbursement Pressures and Healthcare Cost Containment
• Japan's ongoing healthcare cost containment measures and periodic drug price revisions create pricing pressures for ophthalmic pharmaceutical manufacturers. Regular downward adjustments to National Health Insurance drug prices can reduce revenue potential for prescription dry eye treatments and may discourage investment in newer therapies. These reimbursement constraints can limit the commercial viability of innovative formulations and affect the pace at which advanced therapeutic options become widely available to patients.
• Limited Awareness of Chronic Disease Management Needs
• While awareness of dry eye syndrome is growing, many patients still lack understanding of the chronic and progressive nature of the condition. Inconsistent treatment adherence and premature discontinuation of therapy remain common challenges, particularly among patients who experience temporary symptom relief and assume the condition is resolved. The gap between symptom awareness and understanding of the need for sustained management undermines treatment persistence and reduces the long-term therapeutic impact of available products.

COMPETITIVE LANDSCAPE:

• The Japan dry eye syndrome market is characterized by a moderately competitive environment in which established pharmaceutical companies and specialized ophthalmic firms are actively expanding their product portfolios. Competition is driven by innovation in drug formulations, the development of preservative-free and targeted therapeutic solutions, and the pursuit of regulatory approvals for novel treatment approaches. Companies are investing in clinical research to differentiate their offerings through improved efficacy profiles, enhanced patient convenience, and advanced delivery mechanisms. Strategic collaborations, licensing agreements, and partnerships with international ophthalmic innovators are further intensifying competitive dynamics. The market is also influenced by the growing presence of over-the-counter eye care products, which broadens the competitive landscape beyond prescription pharmaceuticals. As the treatment paradigm evolves, market players are refining their strategies to address unmet clinical needs, strengthen brand recognition among healthcare professionals, and capture greater market share across both hospital and retail pharmacy channels.
• KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the Japan dry eye syndrome market?

2. What is the projected growth rate of the Japan dry eye syndrome market?

3. Which disease type held the largest Japan dry eye syndrome market share?

4. What are the key factors driving market growth?

5. What are the major challenges facing the Japan dry eye syndrome market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Japan Dry Eye Syndrome Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Type

• 6.1 Evaporative Dry Eye Syndrome
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Aqueous Dry Eye Syndrome
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

• 7.1 Anti-inflammatory Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Lubricant Eye Drops
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Autologous Serum Eye Drops
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Product

• 8.1 Liquid Drops
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Gel
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Liquid Wipes
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Eye Ointment
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Retail Pharmacies
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Online Pharmacies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 Kanto Region
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Kinki Region
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Central/ Chubu Region
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Kyushu-Okinawa Region
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Tohoku Region
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast
• 10.6 Chugoku Region
  • 10.6.1 Market Trends
  • 10.6.2 Market Forecast
• 10.7 Hokkaido Region
  • 10.7.1 Market Trends
  • 10.7.2 Market Forecast
• 10.8 Shikoku Region
  • 10.8.1 Market Trends
  • 10.8.2 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Policy and Regulatory Landscape

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players

List of Figures

• Figure 2: Japan: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020-2025
• Figure 3: Japan: Dry Eye Syndrome Market: Breakup by Disease Type (in %), 2025
• Figure 4: Japan: Dry Eye Syndrome Market: Breakup by Drug Type (in %), 2025
• Figure 5: Japan: Dry Eye Syndrome Market: Breakup by Product (in %), 2025
• Figure 6: Japan: Dry Eye Syndrome Market: Breakup by Distribution Channel (in %), 2025
• Figure 7: Japan: Dry Eye Syndrome Market: Breakup by Region (in %), 2025
• Figure 8: Japan: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 9: Japan: Dry Eye Syndrome (Evaporative) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 10: Japan: Dry Eye Syndrome (Evaporative) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 11: Japan: Dry Eye Syndrome (Aqueous) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 12: Japan: Dry Eye Syndrome (Aqueous) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 13: Japan: Dry Eye Syndrome (Anti-inflammatory Drugs) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 14: Japan: Dry Eye Syndrome (Anti-inflammatory Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 15: Japan: Dry Eye Syndrome (Lubricant Eye Drops) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 16: Japan: Dry Eye Syndrome (Lubricant Eye Drops) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 17: Japan: Dry Eye Syndrome (Autologous Serum Eye Drops) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 18: Japan: Dry Eye Syndrome (Autologous Serum Eye Drops) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 19: Japan: Dry Eye Syndrome (Liquid Drops) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 20: Japan: Dry Eye Syndrome (Liquid Drops) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 21: Japan: Dry Eye Syndrome (Gel) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 22: Japan: Dry Eye Syndrome (Gel) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 23: Japan: Dry Eye Syndrome (Liquid Wipes) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 24: Japan: Dry Eye Syndrome (Liquid Wipes) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 25: Japan: Dry Eye Syndrome (Eye Ointment) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 26: Japan: Dry Eye Syndrome (Eye Ointment) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 27: Japan: Dry Eye Syndrome (Other Product Types) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 28: Japan: Dry Eye Syndrome (Other Product Types) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 29: Japan: Dry Eye Syndrome (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 30: Japan: Dry Eye Syndrome (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 31: Japan: Dry Eye Syndrome (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 32: Japan: Dry Eye Syndrome (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 33: Japan: Dry Eye Syndrome (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 34: Japan: Dry Eye Syndrome (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 35: Kanto Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 36: Kanto Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 37: Kinki Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 38: Kinki Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 39: Central/ Chubu Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 40: Central/ Chubu Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 41: Kyushu-Okinawa Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 42: Kyushu-Okinawa Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 43: Tohoku Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 44: Tohoku Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 45: Chugoku Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 46: Chugoku Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 47: Hokkaido Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 48: Hokkaido Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 49: Shikoku Region: Dry Eye Syndrome Market: Sales Value (in Million USD), 2020 & 2025
• Figure 50: Shikoku Region: Dry Eye Syndrome Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 51: Japan: Dry Eye Syndrome Industry: SWOT Analysis
• Figure 52: Japan: Dry Eye Syndrome Industry: Value Chain Analysis
• Figure 53: Japan: Dry Eye Syndrome Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Japan: Dry Eye Syndrome Market: Key Industry Highlights, 2025 and 2034
• Table 2: Japan: Dry Eye Syndrome Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
• Table 3: Japan: Dry Eye Syndrome Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
• Table 4: Japan: Dry Eye Syndrome Market Forecast: Breakup by Product (in Million USD), 2026-2034
• Table 5: Japan: Dry Eye Syndrome Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
• Table 6: Japan: Dry Eye Syndrome Market Forecast: Breakup by Region (in Million USD), 2026-2034
• Table 7: Japan: Dry Eye Syndrome Market: Competitive Structure
• Table 8: Japan: Dry Eye Syndrome Market: Key Players